In Brief

Watson adds Actavis for $5.6 bil.; Recordati buys OTCs in Germany; DoJ weighs in on Plan B case; NARC rebranded as ASRC; Korean lawmakers miss another chance on OTC bill; more news In Brief.

Allergan PLC becomes the world’s third-largest generics firm with its $5.60 billion acquisition of Iceland-based Actavis, announced April 25. The deal will expand substantially Watson’s global reach; once it closes, 40% of the Parsippany, N.J., company’s revenues will come from outside the U.S., compared to 16% now. Actavis’ portfolio has more than 830 generic products, and its U.S. subsidiary in Morristown, N.J., manufactures OTCs including bacitracin zinc ointment and children’s ibuprofen oral suspension. Watson is restructuring its leadership to support the Actavis addition. Among the personnel moves, Sigurdur Oli Olafsson, executive VP of global generics, is named president of global generics April 27.

Recordati S.p.A. adds six OTC brands to its portfolio with acquisitions from Johnson & Johnsonsubsidiaries Cilag GmbH and McNeil...

More from Distribution/Supply Chain

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

EUCOPE Wants Simpler Manufacturing Rules And Framework For Combined Trials Under EU Biotech Act

 

EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

EU Emergency Response Authority Needs Bigger Budget To Address Health Threats, Says Industry

 

The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.

More from Compliance

UK’s Plan To Become World’s Third Top Life Sciences Economy Falls Short, Says ABPI

 

The Association of the British Pharmaceutical Industry says that while the government’s newly published Life Sciences Sector Plan includes many positive commitments, they are not enough.

AI In Manufacturing: EU To Revamp GMP Guidance In Light Of Digital Advancements

 

Pharma firms are being encouraged to respond to a European Commission consultation on planned updates to its good manufacturing practice standards which reflect the “rapid advancement” of modern technologies, like AI and digital systems, in drug manufacturing.

Lawyers Weigh In On ‘Sunshine’ Clause In EU Pharma Reform Package

 

The Council of the EU has not taken forward a proposal from the European Parliament that would require companies to disclose the transfers of value they make to health care professionals and health care organizations – lawyers weigh in on the diverging proposals.